LON:AGY Allergy Therapeutics (AGY) Share Price, News & Analysis GBX 4.80 -0.22 (-4.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 4.62▼ 4.8350-Day Range 3.25▼ 652-Week Range 1.20▼ 6.30Volume617,193 shsAverage Volume919,742 shsMarket Capitalization£228.96 millionP/E RatioN/ADividend Yield8.33%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Allergy Therapeutics alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Allergy Therapeutics Stock (LON:AGY)Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More AGY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGY Stock News HeadlinesMay 16, 2024 | msn.comFood Allergy Awareness Week 2024: How can new treatments target an unmet need?May 10, 2024 | markets.businessinsider.comBuy Rating Justified for Aquestive Therapeutics Amidst Innovative Allergy Treatment and Strong Financial ProspectsJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 9, 2024 | tmcnet.comGlobal Skin Allergy Testing Market Expected to Reach $771.5 Million by 2028May 2, 2024 | msn.comSkin patch improves treatment for pediatric milk allergiesApril 27, 2024 | businesswire.comGlobal Skin Allergy Testing Market Report 2024: Revenue Data for 2020-2022, Estimated Figures for 2023, and Forecasts for 2028 - ResearchAndMarkets.comApril 18, 2024 | dailymail.co.ukThe most common 'inhalant' allergiesMarch 29, 2024 | finance.yahoo.comAllergy Therapeutics First Half 2024 Earnings: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023)July 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.March 28, 2024 | lse.co.ukAIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenueMarch 2, 2024 | finance.yahoo.comAllergy Therapeutics plc (AGY.L)November 8, 2023 | morningstar.comAllergy Therapeutics PLC AGYNovember 6, 2023 | marketwatch.comAllergy Therapeutics Extends Cash Runway to End of YearOctober 14, 2023 | finance.yahoo.comAllergy Therapeutics (LON:AGY) dips 10.0% this week as increasing losses might not be inspiring confidence among its investorsOctober 13, 2023 | marketwatch.comAllergy Therapeutics to Raise GBP40.75 Mln; Mandatory Cash Offer TriggeredJuly 31, 2023 | abcnews.go.comRed meat allergy caused by ticks is an 'emerging public health concern': CDCJune 22, 2023 | forbes.comWhat Is A Mold Allergy? Symptoms, Causes And TreatmentsJune 19, 2023 | marketwatch.comAllergy Therapeutics Shares Fall on Going Concern UncertaintySee More Headlines Receive AGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:AGY CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone+44-1903-844700FaxN/AEmployees612Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-30.7Net Income£-50,220,000.00 Net Margins-94.29% Pretax MarginN/A Return on Equity-155.90% Return on Assets-34.76% Debt Debt-to-Equity Ratio37.22 Current Ratio1.40 Quick Ratio1.48 Sales & Book Value Annual Sales£53.26 million Price / Sales4.30 Cash FlowGBX 1.31 per share Price / Cash Flow3.66 Book ValueGBX 1 per share Price / Book4.80Miscellaneous Outstanding Shares4,770,000,000Free FloatN/AMarket Cap£228.96 million OptionableNot Optionable Beta1.34 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Manuel Llobet (Age 59)CEO & Executive Director Comp: $411.98kMr. Shaun Antony Furlong (Age 48)CFO & Executive Director Ms. Beverly LeesGroup Operations DirectorDr. Murray SkinnerChief Scientific OfficerMr. Santiago PuigBusiness Development DirectorMs. Sue BakerHead of Human ResourcesSimon PiggottHead of Clinical ScienceAlan BullimoreHead of Communication & Market DevelopmentMr. Russell PicketGroup Financial ControllerKarley Charlotte Mouatt CheesmanCompany SecretaryMore ExecutivesKey CompetitorsAmryt PharmaLON:AMYTBenchmarkLON:BMKAlliance PharmaLON:APHBeximco PharmaceuticalsLON:BXPAnimalcare GroupLON:ANCRView All CompetitorsInsidersZheqing ShenBought 247,935,056 shares on 11/9/2023Total: £247.94 M ($1.00/share) AGY Stock Analysis - Frequently Asked Questions How have AGY shares performed this year? Allergy Therapeutics' stock was trading at GBX 2.50 on January 1st, 2024. Since then, AGY shares have increased by 92.0% and is now trading at GBX 4.80. View the best growth stocks for 2024 here. How were Allergy Therapeutics' earnings last quarter? Allergy Therapeutics plc (LON:AGY) issued its earnings results on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative trailing twelve-month return on equity of 155.90%. How do I buy shares of Allergy Therapeutics? Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR) and Direxion Daily Gold Miners Index Bear 2x Shares (DUST). This page (LON:AGY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
